Recent

% | $
Quotes you view appear here for quick access.

EDAP TMS SA Message Board

  • biotechal biotechal Jan 14, 2013 12:21 PM Flag

    (NRIFF) Price: 0.065 // FDA decision for Blockbuster drug on March 4 = 500%++ Potential

     

    You can buy this undiscovered Goldmine currently at almost all time low .GLTA

    FDA approval for the "Best in Class topical medication" on March 4 ,2013 . Nuvo has already a great Partnership with Big Player Covidien in place .

    Nuvo will hit profitability this year with 2 new product launches in 2Q 2013 .

    Upcoming Milestones 2013 :

    March 4, 2013 PDUFA date for Pennsaid 2%

    Q2 2013 worldwide launch of Pliaglis by Galderma

    .....

    Nuvo Research (NRI.TO) or (NRIFF)

    Market Cap : $ 36 M
    Cash: $ 12 M
    Price 0.065 $

     Growing revenue with 3 approved pain products:

     Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
    U.S., targeting $8B oral NSAID market

     Pliaglis®: analgesic peelable cream, targeting global cosmetic and
    dermatology markets, partnered with Galderma, worldwide launch
    commencing Q2 2013

    ...........................................

    This topic is deleted.
 
EDAP
2.94+0.02(+0.68%)Sep 28 3:59 PMEDT